SCHEMBL62720

SCHEMBL62720

COc1cc(CCc2cc(NC(=O)c3cnc(N4CC(C)N(CC#N)C(C)C4)cn3)[nH]n2)cc(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.39
NTRK1 P04629 1/20 0.39
RET P07949 1/20 0.39
PDGFRB P09619 1/20 0.39
MARK3 P27448 1/20 0.39
TNK2 Q07912 1/20 0.39
DDR1 Q08345 1/20 0.39
MAP4K2 Q12851 1/20 0.39
MAP3K11 Q16584 1/20 0.39
DDR2 Q16832 1/20 0.39
MARK2 Q7KZI7 1/20 0.39
MAP4K3 Q8IVH8 1/20 0.39
MAP4K1 Q92918 1/20 0.39
AURKB Q96GD4 1/20 0.39
EIF2AK1 Q9BQI3 1/20 0.39
MAP3K20 Q9NYL2 1/20 0.39
STK26 Q9P289 1/20 0.39
TNIK Q9UKE5 1/20 0.39
MAP4K5 Q9Y4K4 1/20 0.39
FGFR3 P22607 10/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63540 1.00 FGFR1 (0.39) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL19327571 0.96 FGFR1 (0.37) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL65207 0.89 FGFR2 (0.42) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL62656 0.88 FGFR1 (0.33) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL64219 0.86 FGFR1 (0.52) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL65470 0.86 FGFR1 (0.41) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL64739 0.80 FGFR1 (0.39) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL64180 0.80 FGFR2 (0.40) FGFR1NTRK1RETPDGFRBMARK3
Hydrochloric Acid SCHEMBL4566202 0.80 FGFR1 (0.38) FGFR1NTRK1RETPDGFRBMARK3
SCHEMBL64686 0.80 FGFR2 (0.45) FGFR1NTRK1RETPDGFRBMARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129391-B2 N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof ASTRAZENECA AB (SE) 2012-03-06 US disclosed
US-20100273811-A1 N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof ASTRAZENECA AB 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273811-A1 N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 FGFR1 823/4885NTRK1 4108/4885RET 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.